Repurposing randomized controlled double-blinded homeopathic pathogenetic trial for determining the expiry of ultra-high diluted homeopathic drugs

Repurposing randomized, controlled, double-blinded homeopathic pathogenetic trial for determining the expiry of ultra-high diluted homeopathic drugs, has been successfully published in the Indian Journal of Traditional Knowledge (indexed in Scopus & Web of Science).

This maybe the first scientific method proposed to determine the expiry of ultra-high-diluted homeopathic medicines published in a Scopus indexed Web of Science journal

Abstract
Unlike conventional pharmaceuticals, ultra-high diluted homeopathic drugs lack measurable molecular content, posing challenges for scientific expiry determination. Currently, global regulatory agencies apply arbitrary expiry durations, risking either premature disposal or prolonged use beyond efficacy. We aimed to propose and test a scientifically valid method for determining the expiry of ultra-high diluted homeopathic drugs by repurposing randomized, double-blind, placebo-controlled pathogenetic trials. We conducted the trial using Allium cepa 30C, a drug with a well-documented pathogenetic profile.

We randomly assigned thirty-six healthy volunteers to: freshly prepared Allium cepa – New Allium cepa, 16-year-old Allium cepa, and the placebo. Participants recorded symptoms over seven days. We extracted and analyzed the symptom elements (location, sensation, modality). We used Jaccard similarity indices to estimate trial noise. Statistical analyses included the Kruskal-Wallis test and post-hoc comparisons. We calculated the effect size using epsilon squared. The New Allium cepa group showed the highest symptom production.

The old Allium cepa group demonstrated a 59.61% reduction in pathogenetic ability compared to the New Allium cepa. While the difference was insignificant (p = 0.108), a large effect size (ε² = 0.193) indicated a potentially meaningful difference. Placebo had the fewest responses and symptom elements. We propose that the repurposed homeopathic pathogenetic trials provide a scientific, reproducible model to assess the expiry of ultra-high diluted homeopathic drugs. This novel approach may aid in developing global regulatory standards and enhance the reliability of homoeopathic practice.

Author Biography
Kurian Poruthukaren, Yenepoya Homeopathic Medical College
Professor & Head of the Department, Department of Repertory

Read the full paper : https://or.niscpr.res.in/index.php/IJTK/article/view/15558

Be the first to comment

Leave a Reply

Your email address will not be published.


*